ArticleEndocrine connections2025
Incidence and risk factors of venous thromboembolism in an adrenocortical carcinoma patient cohort.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy. Venous thromboembolic events (VTE) have been reported in ACC patients. ACC is often associated with endogenous hypercortisolism, which is linked to increased VTE risk. The primary objective of this retrospective study in patients who received treatment for ACC at Amsterdam UMC between 2003 and 2024 was to determine the total incidence of VTE. Secondary objectives included determining the incidence of VTE after adrenalectomy and identifying risk factors for VTE. Patients were categorised into VTE and non-VTE groups. Mann-Whitney U tests, unpaired t-tests, and Chi-square or Fisher's exact tests were used in order to assess differences. Seventy-four patients were included, of whom ten (13.5%) had experienced a VTE during the observation period, amounting to 29 VTEs (CI 13-58) per 1,000 patient-years. All VTEs were pulmonary embolisms. Sixty-four patients underwent adrenalectomy. Fifty (98%) patients, for whom data were available, used peri-operative thromboprophylaxis or anticoagulant therapy. The median duration of peri-operative thromboprophylaxis was 5 days (IQR 4-11, range 0-90). Two patients experienced a VTE within 6 months after surgery (3.3%). Four patients with a VTE (40%) had cortisol-producing ACC (P = 0.83). We conclude that the overall incidence of VTE in ACC patients is high. The incidence of post-operative VTE after adrenalectomy for ACC was lower in this cohort compared with that reported in the literature. No risk factors for VTE were identified; most notably, hypercortisolism was not associated with increased VTE incidence. Our findings expand the literature addressing this issue and reaffirm the importance of the use of peri-operative thromboprophylaxis in ACC patients undergoing adrenalectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.